Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
7-17-2015 12:00 AM

The CTCF Chromatin Organizer is Required for Hindlimb
Development
Katherine L. Rabicki, The University of Western Ontario
Supervisor: Drs. Frank Beier, The University of Western Ontario
Joint Supervisor: Nathalie Berube, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Physiology and Pharmacology
© Katherine L. Rabicki 2015

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Developmental Biology Commons, Musculoskeletal, Neural, and Ocular Physiology
Commons, Musculoskeletal System Commons, and the Other Physiology Commons

Recommended Citation
Rabicki, Katherine L., "The CTCF Chromatin Organizer is Required for Hindlimb Development" (2015).
Electronic Thesis and Dissertation Repository. 2945.
https://ir.lib.uwo.ca/etd/2945

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

THE CTCF CHROMATIN ORGANIZER IS REQUIRED FOR
HINDLIMB DEVELOPMENT
(Thesis Format: Monograph)

By

Katherine Lee Rabicki

Graduate Program in Physiology and Pharmacology
Collaborative Program in Developmental Biology

A thesis submitted in partial fulfillment
of the requirements for the degree of
Master of Science

The School of Graduate and Postdoctoral Studies
Western University
London, Ontario, Canada

© Katherine Lee Rabicki 2015

ABSTRACT
Mutations in chromatin organizer CTCF were identified in patients with intellectual
disability and skeletal defects. Previous studies demonstrated that depletion of CTCF in murine
limb mesenchyme results in apoptosis in the forelimb. The role of CTCF in the hindlimb,
however, is unknown. My objective was to investigate effects of CTCF deletion on
chondrogenesis and skeletal development in the hindlimb. In vitro wild-type micromass cultures
demonstrate that chondrocyte-specific gene expression is delayed in the hindlimb when
compared to forelimbs. Embryonic CtcfFl/Fl;Prx1Cre mice were investigated, and qRT-PCR and
histology were performed on limb buds and long bones. Results show that E12.5 mutant
hindlimb buds have increased apoptosis, but no change in proliferation. Later time points reveal
growth plate defects, and delayed cartilage mineralization in mutant tibiae. Furthermore, mutant
mice have skull defects, shortened long bones and oligodactyly. Overall, data suggest that CTCF
is a key regulator of endochondral/intramembranous ossification and hindlimb development.
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1.0 INTRODUCTION

2

1.1

Skeletal Development
The human skeleton is a remarkable organ composed of over 200 fused and individual

bones that provide coordinated structure, anchor muscles, and protect essential organs1. Skeletal
development is highly regulated, and any disruption in the process can result in severe and
sometimes life-threatening malformations.

The two major routes of bone formation, or

osteogenesis, are intramembranous and endochondral ossification, both of which involve the
transformation of mesenchyme into mineralized bone. Intramembranous ossification occurs in
the developing clavicle, portions of the facial skeleton, and the flat bones of the skull, and
involves direct formation of bone from mesenchymal cells2.

In contrast, endochondral

ossification is characteristic of the majority of bones in the axial and appendicular skeleton and
involves a cartilaginous precursor to mineralized bone3.

1.1.1 Intramembranous Ossification
The calvariae of the skull, clavicle, mandible, and frontal region of the facial skeleton are
all formed through intramembranous ossification, a process that is also critical to certain types of
bone repair4.

Intramembranous ossification commences when cranial neural crest and

mesoderm-derived mesenchymal cells proliferate and then condense into nodules4. Some of
these mesenchymal cells then differentiate into bone-forming osteoblasts and secrete an
extracellular matrix (ECM) called osteoid that is rich in collagen type I (COLI)5. The osteoid
matrix is calcified through the binding of calcium salts, and bony spicules form and radiate
outwards from the start point of ossification5. Compact mesenchymal cells then surround the
developing bone to form a membrane known as the periosteum5. The innermost periosteum cells
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then develop into osteoblasts and continue secreting osteoid matrix, thus enabling the
development of many calcified bone layers5.

1.1.2 Endochondral Ossification
The majority of the human skeleton, and particularly the long bones in the developing
limbs, is formed through endochondral ossification. Endochondral ossification is an osteogenic
process in which an anlage composed of chondrocytes and a cartilage-specific ECM is deposited
and subsequently replaced by mineralized bone (Figure 1.1)3,5.

Like other developmental

processes, endochondral ossification involves numerous growth factors, transcriptional
regulators, and signaling molecules, and is tightly regulated.
Endochondral ossification commences with the commitment of mesodermal cells to the
cartilage lineage. Mesenchymal cells express the transcription factors PAX1 and Scleraxis
(SCX), which are believed to activate cartilage-specific genes, before condensing into nodules7,8.
The precartilaginous condensations then express various growth factors and associated receptors,
including sonic hedgehog (SHH), bone morphogenic proteins (BMP), and fibroblast growth
factor receptor (FGFR), as well as runt-related transcription factor 2 (RUNX2)9. The adhesion
molecules N-cadherin (Cadherin-2; CDH-2), Cadherin-11 (CDH-11), and N-CAM are important
for stabilizing these condensations, which then enables peripheral mesenchymal cells to flatten
and elongate forming the rudimentary perichondrium10,11. The first condensations occur in
humans at 6.5 weeks of development and in mice at embryonic day 10.5 (E10.5)12.
Next, expression of SOX9, the master chondrogenic transcription factor, in the
condensations leads to the differentiation of these cells into chondrocytes13. SOX9 is a DNAbinding protein that, together with L-SOX5 and SOX6, regulates the chondrocyte-specific genes

4

Figure 1.1 Schematic representation of endochondral ossification.
Endochondral ossification involves mesenchymal cells condensing and differentiating into
chondrocytes. Chondrocytes express SOX9, leading to activation of COL2A1 and ACAN which
are critical for the cartilaginous ECM. The chondrocytes line up in characteristic zones known
as the growth plate and undergo rapid proliferation before becoming hypertrophic, characterized
by the expression of COL10A1 and VEGF. The hypertrophic chondrocytes then attract invading
vasculature and bone-forming osteoblasts before undergoing apoptosis or becoming osteoblasts
or osteocytes. Mineralized bone forms in the middle, appropriately known as the primary
ossification centre and as the bone grows outward secondary ossification centres form on either
end. This figure has been modified from Solomon, et al., 20086.

5

6

collagen type II (COL2A1), collagen type IX (COLIX), collagen type XI (COLXI), and aggrecan
(ACAN)14–17.

The chondrocytes then undergo a number of maturation steps involving

proliferation and hypertrophy. Developing cartilage forms a number of characteristic zones
known as the growth plate18. Chondrocytes at the outermost edge of the growth plate are
considered resting chondrocytes, and are small and round in morphology19. The resting zone
chondrocytes proliferate at a slower rate than the neighbouring proliferating zone, but continue to
express high levels of COL2A1 and ACAN19. Adjacent to the resting zone, is the proliferative
zone, in which chondrocytes divide at a rapid rate. The proliferating chondrocytes are flattened
or discoidal in morphology, and form characteristic longitudinal columns20. The proliferating
chondrocytes then exit the cell cycle and increase their volume, becoming prehypertrophic.
Prehypertrophic chondrocytes express genes related to both proliferating and
hypertrophic chondrocytes, and differentiation into hypertrophic chondrocytes is governed by the
Indian hedgehog/Parathyroid hormone-related protein (IHH/PTHrP) negative feedback loop21–23.
IHH regulates cell cycle progression and stimulates PTHrP secretion from both proliferating
chondrocytes and perichondrial cells, which inhibits the onset of hypertrophy. An increase in
chondrocyte hypertrophy is accompanied by increased IHH/PTHrP signaling, thus maintaining
the proliferative pool of chondrocytes. Hypertrophic chondrocytes are round to cuboidal in
shape and up-regulate the expression of RUNX2, which triggers the secretion of a matrix rich in
collagen type X (COL10A1)18. The cell volume increase during hypertrophy is considered a
major determinant of bone length and growth. Hypertrophic chondrocytes release osteopontin
and the extracellular matrix remodeling proteins matrix metalloproteinase-9 (MMP-9), matrix
metalloproteinase-13 (MMP-13) and the aggrecanases ADAMTS4 and ADAMTS524–27.
Additionally, cleavage of the collagen ECM by MMP-9 causes the release of vascular
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endothelial growth factor (VEGF)

24

. At the same time as hypertrophy begins, the cells of the

perichondrium also differentiate into osteoblasts, which enables the formation of the mineralized
bone collar, or periosteum, around the developing skeletal element28. While some hypertrophic
chondrocytes undergo apoptosis, new evidence suggests that some hypertrophic chondrocytes
trans-differentiate into osteoblasts6,29.
Capillaries are recruited into the cartilage anlage from surrounding tissues and the
perichondrium, through a VEGF-dependent pathway28,30.

The invading vasculature is

accompanied by osteoclasts, which act to resorb the ECM while the osteoblasts lay down
mineralized bone30. The first region in a long bone to become mineralized is considered the
primary ossification centre (POC) and forms in the centre of the bone, also known as the
diaphysis. As the developing bone lengthens, secondary ossification centres (SOC) form at
either end, also known as the epiphyses. In humans, the growth plates between the diaphyses
and epiphyses disappears after skeletal maturity is reached, between ages 18 to 25, while in mice
a growth plate is visible in the long bones throughout the entire life of the animal5.

1.1.3 Transcription Factors, Growth Factors, and Signaling Molecules Regulating
Endochondral Ossification
While there are many regulatory factors involved in chondrogenesis, members of the sex
determining region Y (SRY) box (SOX) family, specifically SOX9, L-SOX5, and SOX6, are of
particular importance31. SOX9 is considered the master transcription factor of chondrogenesis
and regulates the differentiation of mesenchymal cells to chondrocytes32. SOX9 expression is
restricted to all chondroprogenitors and differentiated chondrocytes, and is not expressed in
hypertrophic chondrocytes17.

Initial studies on mouse embryo chimeras from Sox9-null
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embryonic stem cells demonstrated that mutant cells were absent from mesenchymal
condensations and failed to express chondrogenic markers including Col2a1 and Acan32.
Furthermore, limb-specific Sox9-null mice display a complete absence of cartilage and bone in
the developing limb, and cartilage-specific Sox9-null mice present with severe generalized
chondrodysplasia and lack L-Sox5 and Sox6 expression17. Interestingly, the SOX9 gene locus has
a complex regulatory region spanning approximately 3Mb upstream and downstream of the
coding region that is highly conserved between humans and mice33. This regulatory region was
first identified in patients with Campomelic Dysplasia (discussed below) when translocations
upstream of the coding region caused reduced SOX9 transcription and severe skeletal defects34.
The regulatory region is flanked by two genes with no known function in chondrogenesis,
KCNJ2 and SLC39A11, and is devoid of other protein-coding genes. This aptly named gene
desert does, however, encode the two long non-coding RNAs BC006965 and D17RIK, both of
which have unknown functions. Overall, data indicate complex regulation of the SOX9 locus,
however, the details are not well understood.

The relatively long distance between some

regulatory elements and the coding regions suggest that DNA looping may be important in the
control of SOX9 transcription.
L-SOX5 and SOX6 are co-expressed with SOX9 in chondroprogenitors and differentiated
chondrocytes, and act cooperatively with SOX9 to activate COL2A1 expression via the COL2A1
enhancer15. Mice null for either L-Sox5 or Sox6 died of neonatal respiratory distress and both
had only a small subset of endochondral elements affected14. L-Sox5-/- mice present with cleft
palate and shortened ribs, as well as delayed mineralization of vertebral bodies and nasal bones14.
Sox6-/- mice also die in the perinatal period and develop severe dwarfism14. Interestingly, L-Sox5
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and Sox6 double mutants have chondrocytes which fail to produce a typical proteoglycan-rich
ECM, and never form growth plates14,15.
A recent study screened the genomic region upstream of the SOX9 gene and reported
three enhancers primarily active in chondrocytes35. These enhancers affect gene expression in
chondrocytes at different stages of their life cycle, including condensed prechondrocytes,
proliferating chondrocytes, and all differentiated chondrocytes35. While the SOX9 protein has
been shown to activate previously reported enhancers by itself, it requires both L-SOX5 and
SOX6 proteins as well as additional factors to robustly activate these enhancers35. Therefore,
evidence demonstrates an elegant synergistic regulation of chondrogenic genes by the SOX trio
of transcription factors.
Another important transcription factor in skeletal development is RUNX2. Formerly
known as CBFA1, RUNX2 is an important regulator of chondrocyte and osteoblast
differentiation36,37. RUNX2 is expressed at a high level in prehypertrophic and hypertrophic
chondrocytes, as well as perichondrial cells, and osteoblasts37. The developing bones in Runx2null mice show decreased chondrocyte maturation and fail to develop osteoblasts, thus they do
not undergo ossification37. RUNX2 is therefore necessary for proper chondrocyte differentiation
and osteogenesis.
Finally, cell cycle machinery and cyclin-dependent kinases have been demonstrated to
control cell proliferation18. Responsible for controlling cell cycle exit and differentiation into
prehypertrophic chondrocytes, p57 is a cyclin-dependent kinase inhibitor of the Kip family38.
p57 functions to inhibit the G1-S phase cyclin-dependent kinases and is expressed at very high
levels in prehypertrophic and hypertrophic chondrocytes38. p57-null mice display shortened,
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thick bones with thinner hypertrophic zones and reduced Col10a1 expression38. p57 is therefore
critical for regulating chondrocyte differentiation and cell cycle exit.

1.1.4 Skeletal Dysplasias
The group of genetic conditions known as skeletal dysplasias encompasses over 200
phenotypes identified in humans, ranging in severity from profound truncations to subtle
alterations in length. Patients affected by skeletal dysplasia have impaired bone growth and
abnormal cartilage, and are often very short in stature. More specifically, the subset of over 150
skeletal disorders affecting cartilage growth and development are termed chondrodysplasias.
The most common form of chondrodysplasia is achondroplasia, caused by a heterozygous gainof-function mutation in the FGFR3 gene39. Achondroplasia is a type of short-limbed dwarfism
in which patients also present with short digits, trident hand, megalencephaly, spinal curvature,
and limitation of elbow extension39.

Interestingly, the growth plates of patients with

achondroplasia have shortened proliferating zones, but do not appear otherwise disorganized as
in other chondrodysplasias39.
Another significant skeletal disorder is campomelic dysplasia (CD), a form of dwarfism
in which the patients suffer from congenital bowing and angulation of the long bones40. CD is an
autosomal dominant disorder caused by loss-of-function mutations in a single allele of the SOX9
gene, leading to haploinsufficiency34,41. Importantly, mutations are reported not only within the
coding region for SOX9, but also in the region upstream42. Patients with CD also often present
with genital ambiguities, 46 XY sex reversal, cleft palate, micrognathia, facial abnormalities, and
only 11 sets of ribs40,43. Ribcage defects lead to respiratory distress during the perinatal period,
accounting for the high mortality rate40. Heterozygous Sox9 mutant mice have been generated
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and are considered a model of CD, as they recapitulate most of the skeletal abnormalities
including bowing of the long bones, cleft palate, hypoplasia, and ribcage defects44.
Other skeletal dysplasias exist and are can be caused by mutations in ECM-related genes.
For example, Schmid metaphyseal dysplasia is caused by mutations in the COL10A1 gene and
results in shortened stature, bowed legs, and irregular growth plates45.

Additionally,

haploinsuffiency of RUNX2 causes the autosomal dominant skeletal dysplasia cleidocranial
dysplasia (CCD)46. Patients with CCD also present with short stature, decreased COL10A1
expression, and diminished hypertrophic zones in their growth plates.

While all of these

conditions severely impact a patient's quality of life, there are also high mortality rates associated
with skeletal disorders.

The use of model systems to deeply investigate endochondral

ossification is therefore an important step in identifying the specific causes of skeletal dysplasia.

1.2

CCCTC-Binding Factor
The large size and complexity of higher eukaryotic genomes necessitates the

sophisticated and dynamic packaging of DNA into stratified levels of organization. DNA is
wrapped around histones to form nucleosomes, which are subsequently looped into higher-order
structures and ultimately form chromosomes residing in defined nuclear territories. Chromatin
acts in a dynamic manner, condensing and de-condensing as a cause and consequence of
transcriptional activity47.

There exists an extensive nuclear network aptly nicknamed the

"loopome" or "interactome," in which local and long-range intra- and interchromosomal loops
form contacts47. While some of these cis- and trans- contacts are stochastic, others appear highly
regulated and have been associated with specific biological processes including X chromosome
inactivation, monoallelic gene expression, and transcription during development48–50. Thus,
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accumulating evidence over the past decade suggests that chromatin structure and the stability of
its 3D architecture significantly affect nuclear functions including transcription, replication,
DNA repair, and mitosis51.
CCCTC-binding factor, commonly known as CTCF, is a highly-conserved transcription
factor that has been heralded as "the master weaver of the genome."47 Evidence demonstrates a
role for CTCF in regulating higher-order chromatin structure and influencing many processes
including X chromosome inactivation, genomic imprinting, long-range interactions, and
transcriptional regulation (Figure 1.2).

Currently there are no reported/published studies

investigating the role of CTCF in cartilage development.

1.2.1 Structure and Regulation
The name CCCTC-binding factor, shortened to CTCF, was determined based on the
initial discovery of CTCF binding to three regularly spaced repeats of the core sequence CCCTC
approximately 200 bp upstream of the transcriptional start site of the chicken c-myc
oncogene's52,53. CTCF is a ubiquitously expressed 82-kDa protein containing 11-zinc finger
motifs54,55. CTCF is highly conserved in most eukaryotes, displaying a 93% identity between
avian and human amino acid sequences, however it is not conserved in yeast and plants55,56. A
study by Klenova et al. reported four CTCF RNA species and six differentially expressed forms
of CTCF protein with molecular masses ranging from 55-130 kDa54. The authors speculated that
alternative mRNA processing was involved in the generation of multiple isoforms of mRNAs
and multiple forms of proteins, and proposed that some forms of the CTCF protein may act
predominantly as repressors or activators with different characteristics54.
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Figure 1.2 Schematic representation of CTCF-mediated chromatin looping
CTCF has been shown to form chromatin loops between genes and their associated enhancers.
These loops can either promote gene expression (left) or prevent the enhancer's association with
genes, thereby inhibiting expression (right).
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The structure of CTCF involves three distinct domains: an N-terminal domain, a Cterminal domain, and the central 11-zinc finger domain55. The central zinc finger domain is
particularly highly conserved, which underscores its importance55. CTCF is regulated, in part,
by distinct modifications of each domain. CTCF can be post-translationally modified by
phosphorylation, poly(ADP-ribosy)lation, and SUMOylation. All strong phosphorylation sites in
CTCF have been mapped to the C-terminal domain and studies have demonstrated that CTCF
can be phosphorylated by protein kinase CK2, leading to abrogation of its repressive activity at
the c-myc promoter57,58. Another group reported poly(ADP-ribosy)lation in vivo, and data from
in vitro studies in breast cancer cells have shown that proper poly(ADP-ribosy)lation is required
for CTCF to associate with and activate the CDKN2A tumour suppressor gene59,60. Finally,
CTCF can be modified at one site in each of the C-terminal domain and the N-terminal domain
by small ubiquitin-like modifier proteins (SUMO).

In contrast to phosphorylation,

SUMOylation of CTCF is important for maintaining the repressive activity of CTCF on the cmyc promoter61.
CTCF function is also regulated through other processes including DNA methylation,
interactions with other proteins, and even interactions with RNAs.

In particular, DNA

methylation plays a critical role in regulating CTCF function, as both cause and consequence. A
study by Wang et al. found that 41% of cell-type-specific CTCF-binding sites are associated
with differential DNA methylation at two specific positions within the CTCF recognition
sequence62. A key example is that of the imprinted H19/IGF2 locus, where the H19 and IGF2
genes are separated by an imprinting control region (ICR). When the ICR is conditionally
methylated on the paternal allele, CTCF cannot bind and the promoter of IGF2 is activated by a
distal enhancer. Conversely, when the ICR is unmethylated, CTCF binds and the enhancer
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activates the H19 promoter63. CTCF has also been shown to form a complex with poly(ADPribose) polymerase 1 (PARP1) and DNA (cytosine-5)-methyltransferase 1 (DNMT1) to maintain
methyl-free CpGs in certain CTCF-bound regions throughout the genome64.
In addition to PARP1, CTCF interacts with other proteins, which provides another level
of complexity to its regulation. In particular, the interaction between CTCF and the multiprotein
cohesin complex has been well-studied. The cohesin complex is ring-shaped and composed of 4
subunits: SMC1, SMC3, RAD21, and SA1/SA265.

Cohesin is known for providing sister

chromatid cohesion during DNA replication and until cell division, but also has roles in
postmitotic cells65. The cohesin complex does not bind DNA directly, but the SCC3 subunit
associates with C-terminal domain of CTCF. Cohesin is present at 50-80% of CTCF-binding
sites, depending on the cell type, and multiple studies have demonstrated that a down-regulation
of cohesin leads to disturbance of the chromatin structure at certain loci, such as the Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR) locus66–69. Cohesin is also required for
the insulator function of CTCF, particularly at the H19/IGF2 locus as discussed in detail below70.
Overall, CTCF is necessary to enrich cohesin binding at specific sites, and cohesin is necessary
to mediate CTCF's insulator activity.70
Finally, in mammalian cells CTCF was shown to form a complex with DEAD-box RNA
helicase p68 (DDX5) and its associated non-coding RNA, steroid receptor RNA activator
(SRA)71. This complex is necessary for stabilizing the cohesin-CTCF interaction at the ICR that
allows for proper imprinted expression of the H19/IGF2 locus, and provides evidence for an
interaction between CTCF and RNAs71.

1.2.2 Function and Roles
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As previously mentioned, CTCF is ubiquitously expressed and binds 55,000-65,000 sites
in mammalian genomes72. Of these binding sites, approximately 5,000 are conserved between
species and tissues, and ~30-60% of binding sites are cell-type-specific73–75. Studies demonstrate
that approximately ~50% of CTCF-binding sites are in intergenic regions, ~15% are proximal to
promoters, and ~35% are intragenic72,74. Described as a "multivalent factor," CTCF exerts
combinatorial control over its different zinc fingers to bind to a wide range of variant
sequences55. For example, zinc fingers 2-7 are utilized in CTCF binding to the chicken c-myc
site, whereas fingers 3-11 are utilized in binding at the human C-MYC site55. This structural
feature of CTCF enables it to serve a diverse set of roles in genome regulation, largely through
altering the genome's topology and 3D architecture. The importance of CTCF in multiple
biological processes is further underscored by CTCF homozygous knockout mice exhibiting
early embryonic lethality prior to implantation76.
Of all the functions assigned to CTCF, its classical role is as an insulator protein;
however, newer evidence suggests insulation is a minor role compared to CTCF's involvement in
regulating chromatin loops in megabase-scale topologically associated domains (TADs).
Insulators are DNA elements that function to block genes from the action of cis-acting elements,
such as enhancers. The well-characterized H19/IGF2 locus discussed above serves as evidence
for CTCF as an insulator63. This locus also provides evidence of CTCF operating by mediating
long-range chromatin interactions. When CTCF binds the ICR, it forms a loop with IGF2 and
blocks enhancers from activating the IGF2 promoter in cis63. Another important piece of
evidence for CTCF as an insulator protein and chromatin looping mediator involves the chicken
β-globin locus, which was shown to contain an insulator sequence77.

CTCF binds to the

insulator and forms a chromatin loop encompassing the β-globin gene and locus control region,
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positioning the elements in such a way that blocks enhancer signals and represses transcription 78.
Beyond its role as an insulator protein, studies have shown CTCF functions as a contextdependent promoter activator and repressor. The original studies on CTCF and the chicken cmyc gene demonstrated through reporter assays that CTCF is a transcriptional repressor52. In
these experiments, deletion of the CTCF binding sequence led to a 4 to 8-fold increase in
transcription of c-myc fusion constructs, thereby providing evidence of repressive activity by
CTCF52. A later study also reported that CTCF binds to and acts as a transcriptional repressor at
the amyloid β-protein precursor (APP) gene promoter79. Interestingly, the APP gene transcript
level is increased in Down's syndrome and in certain brain regions of patients with Alzheimer's
disease, potentially linking CTCF to these neurological pathologies79.
One of the most important processes during development is the precise expression of
Homeobox (HOX) gene clusters. The HOX genes are a group of highly-conserved transcription
factors required for cells to maintain their relative position in the developing embryo, and are
partitioned transcriptionally into discrete clusters.

Mammals have 39 HOX genes in four

clusters, A-D, each on a different chromosome80. The HOX genes pattern the anterior-posterior
axis of the body, and are also critical to limb and genitalia formation. Interestingly, the 5'-end
HOX genes A7-13 are repressed by Polycomb group (PcG) proteins, which utilize repressive
post-translational

histone

modification

H3K27me3,

until

the

correct

developmental

timepoint80,81. Evidence also demonstrates that the HOX clusters are organized into multiple
chromatin loops which are dependent on transcription activity80. In order to understand the
proper temporal and spatial expression of the HOX gene clusters, CTCF was investigated as a
candidate regulatory protein in the process. A highly-conserved binding site for CTCF exists
between genes in the HOXD clusters in human cells, so the role of CTCF as an insulator for the

19

HOX gene clusters was investigated82. Narendra et al. deleted the CTCF binding sites and
showed the expansion of active chromatin into the adjacent repressive domain of the HOXA
cluster in motor neuron progenitor cells81. The study concluded that CTCF partitions the HOX
clusters into architectural domains81. These domains are then acted upon by Trithorax and
Polycomb proteins to establish discrete transcriptional proteins81. Therefore, CTCF is required
to insulate heterochromatin from adjacent euchromatin and to facilitate proper gene expression
patterns of the HOX genes.
This study is in contrast with experiments performed by Soshnikova et al. involving
conditional inactivation of Ctcf in the developing limbs using the Prx1-Cre driver. The mice had
severe developmental defects, including a complete lack of forelimbs83. The authors also noted
that the hindlimb was malformed and had oligodactyly, but did not investigate the hindlimb in
any detail83. In the mutant forelimbs, expression patterns of Hoxa13 and Hoxa11 were not
different from controls, and there was no induction of Hoxb or Hoxc genes in mutant
mesenchyme83. The limbs did show weakened Shh gene expression, which may have affected
Fgf4 expression and the absolute amount of Hoxd transcripts; however the authors felt that this
explanation did not account for the whole effect83. Rather, the investigation showed massive cell
death caused by the impairment of mitochondrial processes and attributed the phenotype to this
effect83.
CTCF has also been implicated in neuroprogenitor differentiation and survival in the
developing mouse brain. A study by Watson et al. elegantly showed that CTCF is required in
the developing telencephalon to prevent massive apoptosis and regulate differentiation and
proliferation of neuroprogenitors84. This study also indicated that the loss of CTCF contributed
to a depletion of the neuroprogenitor pool early in development84. These data provide new
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evidence for the relationship between CTCF-depletion and intellectual disability pathology
discussed below.
Although emerging evidence suggests an important role for CTCF in many tissues and
cell types, little evidence linking CTCF to the developing skeleton has been produced. Notably,
however, was the discovery by Schaub et al. that many CTCF binding sites overlap single
nucleotide polymorphisms (SNP) associated with human height85. Their analysis found that 15
of the 39 SNPs associated with height overlap a ChIP-seq peak for CTCF85. This finding
suggests a possible link between human height, which is partially dependent on proper skeletal
growth, and CTCF. Additionally, recent unpublished data from our laboratory by Bush et al.
demonstrate that the conditional knockout of CTCF in developing cartilage, using the Col2a1Cre driver, severely affects cartilage development. Mutant mice are neonatal lethal and die from
respiratory distress caused by ribcage defects.

These animals also demonstrate severely

malformed limbs and bowing of the long bones. This phenotype resembles that of patients with
CD and the current mouse model of the disease. Furthermore, the CtcfFl/Fl;Prx1Cre mice present
with a slight but significant reduction in Sox9 gene expression and SOX9 protein levels. The
growth plates were also affected in the knockout animals, showing a shortened hypertrophic zone
with fewer and smaller hypertrophic chondrocytes. Together these data suggest that CTCF is
critical for normal cartilage development, potentially through the regulation of Sox9 gene
expression

1.2.3 Pathologies
As the study of epigenetics and chromatin structure grows, so too does the number of
genes implicated in developmental pathologies. A recent article by Gregor and colleagues
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identified de novo mutations in CTCF in four individuals presenting with intellectual disability86.
The mutations varied between individuals, although all were heterozygous. Individuals one and
two had frameshift mutations in exon three and exon six of CTCF, which corresponds to the Nterminal region and fifth zinc finger, respectively. Individual three presented with a missense
mutation in exon nine, which corresponds to the eleventh zinc finger. Finally individual four had
a large deletion containing CTCF and seven additional genes. All four individuals suffered from
developmental delay, and two of the individuals presented with cryptorchidism (undescended
testicles). Interestingly, individuals one, two, and four all had reduced expression of CTCF,
which suggested that haploinsufficiency can cause the intellectual disability phenotype.
Conversely, individual three had unaltered CTCF mRNA and CTCF protein levels, but modeling
programs indicate that the amino acid substitution may affect DNA binding affinity and
specificity. Of particular interest, all four individuals presented with short stature and two
patients had digit abnormalities, suggesting that hypomorphic mutations in CTCF also affect
proper skeletal development.
Gene mutations in the cohesin network also leads to a family of rare human diseases
known as cohesinopathies. The two cohesinopathies that have been studied in depth are Cornelia
de Lange syndrome (CdLS) and Roberts syndrome.

CdLS is an autosomal dominant

neurodevelopmental disorder most commonly caused by mutations in the gene encoding
NIPBL87. While not a subunit of cohesin, NIPBL is required to load cohesin onto chromatin 87.
Patients with CdLS are characterized by intellectual disability, facial dysmorphism, upper limb
abnormalities, and growth retardation, however the disease is thought to result from
transcriptional alterations, not from problems in sister chromatid cohesion87. Roberts syndrome
is phenotypically related to CdLS, however it is autosomal recessive and caused by mutations in
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the gene encoding ESCO2, another cohesin-associated protein required for the establishment of
cohesion between sister chromatids following DNA replication87.

Roberts syndrome is

extremely rare and severe, patients also present with craniofacial abnormalities, limb reduction,
and growth retardation87. In patients with Roberts syndrome, both sister chromatin cohesion and
mitosis are affected.

All these conditions, therefore, underscore the importance of proper

epigenetic regulation and chromatin cohesion via the cohesin complex during skeletal
development.

1.3

Governing Rationale and Objectives
Emerging evidence shows that CTCF is critical for the proper regulation of multiple cell

and tissue types. However, the role of CTCF in the developing hindlimb and skeleton has never
before been investigated. Studies show a role for CTCF in regulating the HOX gene clusters,
which are critical for limb development, and other studies have demonstrated that CTCF is
required to prevent massive apoptosis in the developing forelimb81,83.

Furthermore, our

unpublished research reveals that CTCF is required for the maintenance of Sox9 expression in
developing cartilage and that loss of CTCF in cartilage causes campomelia. Thus, both these
CTCF-deficient animal models and de novo human CTCF mutations suggest that CTCF
regulates limb and cartilage development. Given that CTCF deletion in the forelimb of mice
using the Prx1-Cre driver line caused excessive apoptosis and loss of tissue, my objective was
to investigate the effects of CTCF deletion on chondrogenesis and skeletal development in
the hindlimb of CtcfFl/Fl;Prx1Cre mice.

The CtcfFl/Fl;Prx1Cre hindlimb presents an

intermediate phenotype that falls in between the completely abrogated CtcfFl/Fl;Prx1Cre
forelimb, and the slightly bowed CtcfFl/Fl;Col2Cre hindlimb.

My first objective was to
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investigate differences in the onset of chondrogenic gene expression in micromass cultures
established from wild-type forelimbs versus hindlimbs. Secondly, I assessed gene expression
differences and alterations in development of the hindlimbs and long bones of the
CtcfFl/Fl;Prx1Cre mice. This thesis, to the best of my knowledge, represents the first in-depth
characterization of the role of CTCF in the developing hindlimb of CtcfFl/Fl;Prx1Cre mice.
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2.0 MATERIALS & METHODS
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2.1

Timed Pregnant CD1 Mice
Timed pregnant CD1 mice were purchased from Charles River Laboratories (Sherbrooke,

Quebec) and were sacrificed for experimentation by carbon dioxide asphyxiation. The use of
animals for experimentation was approved by Animal Care and Veterinary Services at Western
University.
2.2

Murine Micromass Cultures
Micromass cultures were prepared as described with minor modifications88,89. Forelimb

and hindlimb buds of up to 12 embryonic day 10.5 (E10.5) CD1 mouse embryos were dissected
in Puck's Saline Solution A buffer (PSA) and diced using a sterile razor blade. The limb buds
were then digested in 10 mg/ml dispase (Roche Molecular Biochemicals, Indianapolis, IN, USA)
solution containing 10% fetal bovine serum (FBS; Sigma-Aldrich, Oakville, ON, Canada)/PSA
for 2 hours at 37°C and shaken at 100 rpm, with vortexing every 15 minutes. After digestion, the
enzymatic reaction was neutralized with 2:3 Dulbecco's Modified Eagles Medium (DMEM):F12
media (Sigma-Aldrich) containing 10% FBS, 0.25% Penicillin (10,000 units/ml; SigmaAldrich)/Streptomycin (10,000 μg/ml; Sigma-Aldrich), and 0.25% L-glutamine (200mM; SigmaAldrich). Digested tissue was passed through a 40 μm cell strainer (Falcon, Lincoln Park, NJ)
before centrifugation for 5 minutes at 23°C and 1000 rpm. Cells were then re-suspended in
DMEM:F12 media containing 10% FBS, 0.25% Penicillin/Streptomycin, and 0.25% Lglutamine, and counted using a haemocytometer (Hausser Scientific Partnership, Horsham, PA,
catalogue number 3200). Cells were then centrifuged again for 5 minutes at 23°C and 1000 rpm,
re-suspended at a final concentration of 2.5x107 cells/ml, and plated in eight 10 μl droplets per
well in a six-well NUNC delta surface cell culture plate (Thermo Scientific, Burlington, ON,
Canada). Cells adhered to the plate during a 1-hour incubation period at 37°C and 5% CO2.
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Finally, 2 ml of 2:3 DMEM:F12 media containing 10% FBS, 0.25% Penicillin/Streptomycin, and
0.25% L-glutamate was added to each well. Micromass cultures were grown for up to 60 hours
with media changed every 24 hours.
2.3

CtcfFl/Fl;Prx1Cre Mice
All studies were conducted in accordance with the policies and guidelines set forth by the

Canadian Council on Animal Care and were approved by the Animal Use Subcommittee of
Western University. Mice were housed in Animal Care and Veterinary Services facilities at
Western University and cared for according to protocol number 2007-045 (Appendix A). Mice
were housed in standard cages and maintained on a 12-hour light/dark cycle, with rodent chow
and water available ad libitum. Timed matings involved one male CtcfFl/+;Prx1Cre and one
female CtcfFl/Fl mouse per cage, placed together at 5:00 pm and separated the following morning
at 9:00 am (Figure 2.1). Pregnant females were sacrificed and embryos were collected at
embryonic day 12.5 (E12.5), 13.5 (E13.5), 15.5 (E15.5), and 18.5 (E18.5). Pups were also
collected at post-natal day 0 (P0). Litters containing a wild-type, heterozygote, and homozygote
conditional knockout mouse were considered one trial (N=1). Euthanasia was performed on the
pregnant dames by carbon dioxide asphyxiation or lethal injection of 270 μg Euthanyl/g body
weight (Animal Health Inc.) for P0 pups.
Tissue for genotyping was collected from tail clippings of euthanized embryos and pups.
Clippings were digested in Eppendorf tubes with 100 μl of Solution A (25 mM NaOH, 0.5 M
EDTA at pH 6.0) for 1 hour at 95°C before 100 μl of Solution B (40 mM Tris-HCL at pH 6.0)
was added.

Polymerase chain reaction (PCR) was performed using oligonucleotides Ctcf

forward primer (5'- CTAGGAGTGTAGTTCAGTGAG -3'), Ctcf reverse primer (5'GCTCTAAAGAAGGTTGTGAGT -3') and Cre forward primer
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Figure 2.1 Schematic representation of mouse breeding strategy.
The Cre/loxP recombination system was utilized in C57BL/6 mice to produce conditional Ctcf
knockout animals. Female mice homogenous for the floxed Ctcf locus were bred with male mice
heterogeneous for the floxed Ctcf locus and expressing Cre recombinase under the control of the
Prx1 enhancer. After Cre-mediated recombination, Ctcf-null pups were produced (KO) and
compared to littermates lacking Cre as controls.
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(5'-CCTGGAAAATGCTTCTGTCCG

-3'),

Cre

reverse

primer

(5'-

CAGGGTGTTATAACAATCCC. -3') for amplification. All oligonucleotides were purchased
from Sigma-Aldrich and all additional genotyping reagents were purchased from Roche.
Samples were run in a MyCyclerTM thermal cycler (Bio-Rad, Mississauga, ON, Canada). PCR
protocol included a 3-minute denaturing step at 95°C, followed by 34 cycles of 95°C for 45
seconds, 58°C for 30 seconds, and 72°C for one minute, before a 10-minute incubation at 72°C.
PCR products were run on a 1.5% agarose (Bio-Shop, Burlington, ON, Canada), 0.005%
Ethidium bromide (Sigma-Aldrich) gel at 120 V for 1 hour. Bands were visualized using a Gel
DocTM EZ System (Bio-Rad).
2.4

Skeletal Preparation
Following euthanasia, P0 mice were skinned, eviscerated, and fixed in 70% ethanol for

24 hours at room temperature. The solution was then changed to acetone for 24 hours at room
temperature before the bodies were placed in staining solution (0.05% Alizarin Red (SigmaAldrich), 0.015% Alcian Blue (Sigma-Aldrich), 5% Acetic Acid and 70% ethanol) for five days.
Upon removal of staining solution, soft tissue was digested by graded potassium hydroxide
solutions placed on a rocker at room temperature. Finally, clean skeletons were stored in a 1:1
Glycerol:70% ethanol solution.
Skeletons were visualized using a Leica S6D Stereomicroscope with a 0.63x demagnifying lens and images were taken using a Leica EC3 digital camera. Total long bone
length and mineralized zone length were measured using the Leica Application Suite software.
2.5

Tissue Processing
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Following euthanasia, the skulls, forelimb and hindlimb buds of E12.5 wild-type mice
were microdissected in phosphate buffered saline (PBS) and fixed in 4.0% paraformaldehyde
(PFA) for 15 minutes. Following fixation, tissues were submerged in a 30% sucrose in PBS
solution and kept for 24 hours at 4°C. Tissues were then embedded in Tissue-Tek® O.C.T
(Optimal Cutting Temperature; VWR International, Mississauga, ON, Canada) compound and
stored at -80°C until cryosectioning was completed at the Molecular Pathology Core Facility,
Robarts Research Institute (London, ON, Canada).
Additionally, following euthanasia, tibiae were dissected from E15.5 conditional
knockout mice and controls in PBS and fixed in 4.0% PFA for 24 hours. Following fixation, the
solution was replaced with 70% ethanol, and bones were labeled using 2% Mercurochrome
(Fisher Scientific, Toronto, ON, Canada) before being sent to the Molecular Pathology Core
Facility, Robarts Research Institute, for tissue processing, paraffin embedding, and sectioning.
2.6

Histology
Paraffin sections were de-waxed in xylene and rehydrated for staining in graded series of

ethanol solutions (100%, 100%, 95%, 70%) and then water. Histological staining was performed
on sections of E15.5 tibiae using Safranin-O/Fast Green, and von Kossa staining. For SafraninO/Fast Green staining of proteoglycans, sections were incubated in Hematoxylin (Fisher
Scientific) for 2 minutes, then washed in running tap water for 10 minutes. Slides were then
incubated in 0.01% Fast Green (Fisher Scientific) for 25 minutes, dipped in 1% Acetic Acid five
times, and incubated in 0.1% Safranin-O (Fisher Scientific) for 7 minutes. Slides were then
dehydrated and cover slips were applied using SHUR/MountTM Liquid Mounting Medium
(VWR). Representative images of tibia sections were taken using a Leica DM1000 microscope.
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Sections processed for von Kossa staining were incubated with 5% silver nitrate solution
under light for 1 hour, then were washed with water and incubated in 5% sodium thiosulfate for
5 minutes. Slides were then rinsed in distilled water, counterstained with Methyl Green (Fisher
Scientific), dehydrated and cover slips were applied using SHUR/MountTM Liquid Mounting
Medium (VWR). Representative images of tibia sections were taken using a Leica DM1000
microscope.
2.7

Immunohistochemistry and Immunofluorescence
Immunohistochemistry (IHC) was performed on E15.5 tibiae using antibodies against

p57 (Santa Cruz Biotechnology, Dallas, TX, USA). Sections were de-waxed and rehydrated in
xylenes and a graded series of ethanol, then incubated in 3% hydrogen peroxide in methanol for
15 minutes at room temperature. Antigen retrieval was performed by incubating sections in
0.1% Triton-X (Sigma-Aldrich) at room temperature for 13 minutes before sections were
blocked in 5% goat serum in PBS-0.1% Tween (PBST; Sigma-Aldrich) for 1 hour at room
temperature. Primary antibody against p57 was diluted in blocking solution according to its
optimized concentration of 1:200. Sections were incubated with the primary antibody overnight
in a humidified chamber at 4°C before being washed in dH20 the following day. Sections were
then incubated in horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary
antibody (Santa Cruz Biotechnology) diluted 1:200 in PBS for 1 hour at room temperature.
Visualization was performed using 3,3'-Diaminobenzidine (DAB) substrate solution (Dako,
Burlington, ON, Canada) before being counterstained with Methyl Green (Fisher-Scientific) in
0.1 mM sodium acetate buffer for 10 minutes. Sections were then dehydrated and cover slips
were applied using SHUR/MountTM Liquid Mounting Medium (VWR). Representative images
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of tibia sections were taken using a Leica DM1000 microscope and Leica Application Suite was
used for measurements of the unstained resting and proliferating chondrocyte zones.
Immunofluorescence (IF) was performed on frozen E12.5 hindlimb bud sections for
CTCF, SOX9, and proliferating cell nuclear antigen (PCNA). Sections were thawed at room
temperature for 1 hour, baked at 42°C for 30 minutes, then rehydrated in PBS at room
temperature for 5 minutes. Antigen retrieval was performed by incubating slides in 10 mM
sodium citrate, pH 6, at 95°C for 10 minutes, then cooled for 20 minutes before blocking with
5% donkey serum or goat serum in PBST for 1 hour at room temperature. Primary antibody
against CTCF (rabbit anti-CTCF; Cell Signaling Technologies, Danvers, MA, USA) was diluted
in blocking solution according to its optimized concentration of 1:400. Primary antibody against
SOX9 (goat anti-SOX9; R&D Systems, Minneapolis, MN, USA) was diluted in blocking
solution according to its optimized concentration of 1:300. Primary antibody against PCNA
(mouse anti-PCNA; Cell Signaling Technologies) was diluted in blocking solution according to
its optimized concentration of 1:400.

Sections were incubated with the primary antibody

overnight in a humidified chamber at 4°C before being washed in dH20 the following day.
Sections were then incubated with donkey anti-goat IgG (Life Technologies, Burlington, ON,
Canada) or goat anti-mouse IgG (Life Technologies) secondary antibody diluted 1:200 in PBS
for 1 hour at room temperature, prior to applying cover slips with VECTASHIELD Mounting
Medium with DAPI (Vector Laboratories, Burlington, ON, Canada). Images of CTCF staining
were captured with a digital camera (ORCA-ER; Hamamatsu, Middlesex, NJ, USA) on a Leica
DMI 6000b microscope. Open-Lab imaging software (PerkinElmer, Waltham, MA, USA) was
used for image capture, and processing was performed using Volocity software (PerkinElmer).
Images of SOX9 and PCNA staining were captured with a Leica DMRA2 fluorescence
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microscope. SOX9- and PCNA-positive cells were counted in a region of interest using ImageJ
software (National Institutes of Health, Bethesda, MD, USA), and the positively stained cells
were taken as a percentage of the total cells (DAPI-positive cells) in the area.
2.8

TUNEL Staining
TUNEL staining was performed on E12.5 hindlimb bud sections using the In Situ Cell

Death Detection Kit, Fluorescin (Roche) according to the manufacturer's instructions. Cover
slips were then applied using VECTASHIELD Mounting Medium with DAPI (Vector), and
representative images were visualized with a Leica DMRA2 fluorescence microscope. TUNELpositive cells were counted in a region of interest using ImageJ software (National Institutes of
Health), and the positively stained cells were taken as a percentage of the total cells in the area.
2.9

RNA Isolation and Quantitative Real-Time Polymerase Chain Reaction
Total RNA was isolated from wild-type limb bud micromass cultures at 0, 12, 24, 36, 48,

and 60 hours after plating. Total RNA was also isolated from whole E12.5 and E13.5 hindlimb
buds of conditional knockout embryos and control littermates. In both cases, TRIzol reagent
(Life Technologies) was used to extract RNA according to the manufacturer's instructions. A
NanoDrop 2000 spectrophotometer (Thermo Scientific) was used to quantify RNA. 500 ng of
RNA were reverse transcribed into complementary DNA (cDNA) using the iScript cDNA
Synthesis kit (Bio-Rad) according to the manufacturer's instructions.
Gene expression was assessed by real-time PCR using a Bio-Rad CFX384 RT-PCR
system. PCR reactions were run in triplicate, using 0.4 μl of cDNA per reaction and 0.1 μl
forward and reverse primers (100 μM). PCR parameters involved an initial denaturing step at
95°C for 3 minutes, followed by 40 cycles of denaturing at 95°C for 10 seconds, and
annealing/elongating at 58°C for 20 seconds. Relative gene expression was calculated using the
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ΔΔCt normalized for input using β-actin and expressed relative to the 0 h time point in
micromass cultures, or E12.5 control in hindlimb buds.
Relative gene expression was determined for Ctcf, type II collagen (Col2a1), the
proteoglycan aggrecan (Acan), the Sox trio (Sox9, Sox5, Sox6), long non-coding RNAs
BC006965 and D17Rik, the two genes bordering the Sox9 locus: Kcnj2 and Slc39a11, Ncadherin (Cdh2) and cadherin-11 (Cdh11; Table 2.1). Standard curves were generated to control
for primer efficiency, and the specificity of the primers was determined by melt curve analysis
(0.5°C/5 seconds).
2.10

Statistical Analysis
All data collected were from a minimum of three independent trials.

Data were

expressed as mean ± SD. P values less than 0.05 were considered significant (*). Statistical
significance was determined with a t-test, one-way ANOVA, or two-way ANOVA followed by a
Tukey's multiple comparison test using GraphPad Prism version 6.0 (GraphPad Software, San
Diego, CA, USA).
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Table 2.1 Primers for Quantitative Real-Time PCR
NCBI Gene Symbol
β-actin Fwd
β-actin Rev
Ctcf Fwd
Ctcf Rev
Sox9 Fwd
Sox9 Rev
Sox5 Fwd
Sox5 Rev
Sox6 Fwd
Sox6 Rev
Col2a1 Fwd
Col2a1 Rev
Acan Fwd
Acan Rev
BC006965 Fwd
BC006965 Rev
D17Rik Fwd
D17Rik Rev
Kcnj2 Fwd
Kcnj2 Rev
Slc39a11 Fwd
Slc39a11 Rev
Cdh2 Fwd
Cdh2 Rev
Cdh11 Fwd
Cdh11 Rev

Primer Sequence 5' » 3'
CTGTCGAGTCGCGTCCACCC
ACATGCCGGAGCCGTTGTCG
GAGCCTGCTGTAGAAATTGAA
CCAATAGTCCTGGTGCCGAGCAAGGCCCC
CTCTGGGCAAGCTCTGGA
GTCGGTTTTGGGAGTGGTG
CCTGAAGCAGAGGAAGATGG
CTCCTTCTCAGCGAGGCTCT
CTGAGCAACTGAGGACTGA
AGCCATTCATTGCTTTGCTT
AAGGGTCACAGAGGTTACCC
GTCCTCTCTCACCAGGCAG
GCTGCAGTGATCTCAGAAGAAG
CACCAGCAGTACCACCTCCT
GTCAAGTCTTGGGCCTGATG
CGCACAGAAACGTACCATTG
CGCACAGAAACGTACCATTG
CTTGCTCTTGTTCCATGCAG
TAATCCCCACTTCCACTCCA
TCGGTGAAGACACACCAAAA
TTCCAGAGGGTCTTGCTGTT
GCTCAGCTGTCCATACCAGA
TGCCAGAAAACTCCAGAGGA
TCGATCCAGAGGCTTTGTGA
GACACAGCCAATGGACCAAG
ACGTCGGGCATATACTCCTG
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3.0 RESULTS
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3.1 Micromass cultures from wild-type forelimb and hindlimb buds showed patterns of
increasing chondrogenic gene expression over 60 hours post-plating.
CtcfFl/Fl;Prx1Cre mice were originally described by Soshnikova et al. in 2010 during a
study on CTCF and Hox gene regulation. This study described the mutant mice as having
truncated forelimbs and a milder hindlimb phenotype: shortened long bones and oligodactyly
(reduced number of digits). Given the startling difference between the forelimb and hindlimb
phenotypes, I began my investigation by examining key chondrogenic genes in wild-type
micromass cultures from E10.5 forelimb and hindlimb buds. Micromass cultures replicate early
chondrogenesis in vitro, thus I explored the possibility of differential gene expression between
limbs as a contributor to phenotypic severity. RNA was collected from micromass cultures
every 12 hours post-plating, and qRT-PCR was utilized to examine gene expression changes. I
first set out to examine expression differences in the Sox gene trio because of their critical role in
differentiation of mesenchymal cells into chondrocytes. Sox9 gene expression in the forelimb
showed a significant 3.5-fold and 4-fold increase at 48 hours and 60 hours post-plating, while
expression showed a trend in increasing expression in the hindlimb, although the increase was
not statistically significant (Figure 3.1A). The increase in Sox9 expression was also steeper in
the forelimb than in hindlimb micromass cultures, particularly between 12-24 hours post-plating
(Figure 3.1A). Sox5 transcript levels showed a pattern of increasing expression in forelimb
micromass cultures until 24 hours, then maintained steady expression levels until 36 hours before
declining back to baseline levels by 60 hours post-plating (Figure 3.1B). Conversely, Sox5
expression in hindlimb micromass cultures increased slightly until 24 hours, plateaued until 48
hours, and then increased again at 60 hours post-plating (Figure 3.1B). However, trends seen in
Sox5 expression in both forelimb and hindlimb cultures were not statistically significant.
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Figure 3.1 Sox9, Sox5, and Sox6 gene expression in micromass cultures from wild-type
forelimbs and hindlimbs.
Micromass cultures from E10.5 forelimb buds and hindlimb buds were plated and collected at
12-hour intervals. RNA from the cultures was used to perform qRT-PCR reactions to examine
Sox9, Sox5, and Sox6 gene expression.

A. Forelimb micromass cultures demonstrated a

significant increase in Sox9 expression at 48 hours and 60 hours post-plating. Although there
was no significant difference in Sox9 transcript in the hindlimb, data suggest a trend showing a
steady increase in expression in both cultures after 12 hours. B. There was no significant
difference in Sox5 gene expression in either forelimb or hindlimb micromass cultures over time;
however, a trend suggests increasing Sox5 expression in hindlimb micromass cultures. Sox5
expression in forelimb micromass cultures appeared to increase immediately after plating then
decreases after 36 hours. C. Although there was no significant difference in Sox6 transcript
levels in either forelimb or hindlimb micromass cultures over time, data suggest a trend showing
a steady increase in expression in both cultures after 0 hours. All data represented are mean ±
SD; * = P < 0.05. N=3 for forelimb, N=6 for hindlimb.
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Finally, Sox6 expression showed a trend of increasing expression in both forelimb and hindlimb
micromass cultures, but while forelimb cultures showed a decrease in expression from 36-48
hours before increasing again by 60 hours, hindlimb micromass cultures demonstrated a
relatively steady increase in transcript expression over the time course (Figure 3.1C). These
results indicate that the overall patterns of Sox trio gene expression are similar between forelimb
and hindlimb, although Sox9 expression increased more rapidly in the forelimb micromass
cultures which suggests chondrogenesis is occurring more rapidly.
To investigate potential differences between limbs in chondrogenic genes downstream of
the Sox trio, transcript levels of the cartilaginous ECM genes Acan and Col2a1 were analyzed.
Expression profiles of forelimb micromass cultures showed a robust and steady increase in Acan
expression that reached a significant 50-fold increase at 60 hours post-plating, when compared to
0 hours (Figure 3.2A). Acan expression levels in hindlimb micromass cultures also increased
approximately 4-fold over 60 hours, although these results did not reach significance (Figure
3.2A). Moreover, Col2a1 transcript levels showed a significant 180-fold increase at 60 hours
post-plating in the forelimb micromass cultures (Figure 3.2B). Hindlimb micromass cultures
also showed a significant increase in Col2a1 expression, although the increase was
approximately 75-fold (Figure 3.2B). Taken together, these results demonstrate that forelimb
and hindlimb micromass cultures show similar overall patterns of cartilaginous ECM gene
expression, although the fold-change appears to be higher, and the time course faster, in forelimb
micromass cultures than in hindlimb.
Given our lab's unpublished data suggesting a role for CTCF in regulating gene
expression at the Sox9 locus, I set out to investigate expression of the long non-coding RNA
BC006965, whose gene is located directly upstream of the Sox9 gene, overlapping with genomic
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Figure 3.2 Relative Acan and Col2a1 expression in wild-type micromass cultures from
forelimbs and hindlimbs.
Micromass cultures from E10.5 forelimb buds and hindlimb buds were plated and collected at
12-hour intervals. RNA from the cultures was used to perform qRT-PCR reactions to examine
Acan and Col2a1 gene expression. A. Acan expression showed a steady and significant increase
in forelimb micromass cultures 60 hours post-plating when compared to expression levels at 0
hours. Hindlimb micromass cultures showed no significant differences, however data show a
trend indicating an increase in Acan expression over the time course.

B.

Col2a1 gene

expression was significantly increased in forelimb and hindlimb micromass cultures at 60 hours
post-plating when compared to 0 hours. All data represented are mean ± SD; * = P < 0.05. N=3
for forelimb, N=6 for hindlimb.
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CTCF binding sites identified by us (Bush et al., in prep). In forelimb micromass cultures,
BC006965 expression showed a trend of increasing transcript levels until 36 hours post-plating,
then a slight decrease in expression between 36-48 hours (Figure 3.3A). Conversely, transcript
levels in the hindlimb micromass cultures appeared to show a slight but steady increase over
time, although the fold-change is not statistically significant (Figure 3.3A). Interestingly, a
comparison of the expression patterns of Sox9 and BC006965 in hindlimb micromass cultures
revealed that both transcripts are up-regulated over the time course, with similar relative
expression levels at each time point (Figure 3.3B). These results indicate that BC006965
expression may be regulated in a similar manner to Sox9 gene expression in the developing
hindlimb.
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Figure 3.3 Expression of the long non-coding RNA BC006965 in wild-type forelimb and
hindlimb micromass cultures.
Micromass cultures from E10.5 forelimb buds and hindlimb buds were plated and collected at
12-hour intervals. RNA from the cultures was used to perform qRT-PCR reactions to examine
gene expression of BC006965, a long non-coding RNA proximal to the Sox9 locus.

A.

BC006965 expression did not show a significant increase in either forelimb or hindlimb
micromass cultures, however trends indicate a slight increase in expression over the time course.
B. The trend in steadily increasing gene expression levels of BC006965 in hindlimb micromass
cultures is similar to the expression of Sox9 in hindlimb micromass cultures across the 60 hour
time course. All data represented are mean ± SD; * = P < 0.05, N=3 for forelimb, N=6 for
hindlimb.
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3.2 Validation of Ctcf inactivation in hindlimb buds of E12.5 CtcfFl/Fl;Prx1Cre embryos and
the published phenotype.
To validate the CtcfFl/Fl;Prx1Cre mouse published by Soshnikova et al., I began by
confirming the loss of CTCF protein and Ctcf transcript levels through immunostaining and
qRT-PCR on hindlimb buds at age E12.5. The previous study had focused on the developing
forelimb and reported a 90% loss of Ctcf mRNA in mutant forelimbs at E10.75, but had not
examined the hindlimb. To confirm the loss of CTCF protein, immunofluorescent staining for
CTCF was performed on cryosections from Ctcf-null and control hindlimb buds.

Control

hindlimb buds showed the ubiquitous expression of CTCF protein and knockout hindlimb buds
showed a reduction in CTCF protein in the mesoderm, with normal CTCF protein expression in
the surrounding ectodermal tissue (Figure 3.4A,B). Ctcf gene expression was also examined and
revealed a significant 70% reduction in mRNA in the Ctcf-null hindlimb bud (Figure 3.4C).
These results confirm that CTCF expression is decreased in the hindlimb buds of
CtcfFl/Fl;Prx1Cre compared to controls.
The published phenotype of the CtcfFl/Fl;Prx1Cre mice was then validated at various
developmental time points. At E15.5, Ctcf-null embryos had truncated forelimbs and shortened
hindlimbs with oligodactyly, features that were also present at P0 (Figure 3.5A,B). The mutant
embryos also presented with a brain protrusion above their skull at E15.5, which was still
apparent at E18.5, but absent after birth, likely due to shearing during delivery (Figures 3.5A,B,
3.6A,B). Furthermore, the knockout mice were dead at birth and displayed holes of various sizes
in the skull (Figure 3.6B). Interestingly, the Ctcf-null mice appeared to have looser skin than
their control counterparts, as evidenced by the wrinkled skin around their necks (Figure 3.5B).
Thus, the phenotypes of the CtcfFl/Fl;Prx1Cre mice are in accordance with those previously
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described by Soshnikova et al., although this is the first report on the skull defect and potential
skin abnormalities.
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Figure 3.4 Ctcf gene expression and CTCF protein distribution in E12.5 CtcfFl/Fl;Prx1Cre
hindlimb buds.
A. Immunofluorescent staining for CTCF in the hindlimb bud at E12.5 from control animals
demonstrated uniform expression of CTCF protein throughout the developing limb. B. Ctcf-null
hindlimb buds displayed a noticeable reduction in CTCF protein at E12.5 when compared to
littermate controls. C. qRT-PCR results from whole E12.5 hindlimb buds showed a significant
reduction in Ctcf gene expression in knockout animals when compared to littermate controls.
Data represented are mean ± SD; * = P < 0.05, N=3. Scale bar = 200 μm at 10x, 100 μm at 20x
zoom.
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Figure 3.5 Gross examination of CtcfFl/Fl;Prx1Cre animals and littermate controls at E15.5
and P0.
A. Whole body inspection of Ctcf-null animals showed a severely shortened forelimb, hindlimb
abnormalities, and a protrusion above the skull at E15.5. B. At P0, Ctcf-null animals showed
severe limb defects and display an open skull vault. Scale bar = 5 mm
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Figure 3.6 Gross examination of the skulls of CtcfFl/Fl;Prx1Cre mice and littermate controls
at E18.5 and P0.
A. Gross examination of the heads of E18.5 pups just prior to birth indicated that tissue still
covers the protruding brain in Ctcf-null animals. B. Examination of the heads after birth,
however, revealed one knockout mouse with an intact brain protrusion (left), and holes of
variable sizes in the skull vault of other Ctcf-null pups. Scale bar = 3 mm

53

54

3.3 CtcfFl/Fl;Prx1Cre hindlimbs had significantly higher levels of apoptosis than littermate
controls at E12.5, but no differences in proliferation.
Soshnikova et al. previously reported that CtcfFl/Fl;Prx1Cre mice had significantly higher
levels of apoptosis in their forelimb buds at E11.5, but did not investigate cell death in the
hindlimb.

To validate this finding and investigate potential apoptosis in the hindlimb, a

fluorescent TUNEL stain was used in forelimb and hindlimb cryosections from E12.5
CtcfFl/Fl;Prx1Cre and control embryos. As previously reported, the mutant forelimb showed
significantly more apoptosis in a representative area when compared to control forelimbs
(Figure 3.7A, B). Mutant hindlimbs also showed higher levels of apoptosis than corresponding
littermate controls, but significantly less than mutant forelimbs (Figure 3.7A, B).
A reduction in proliferation in the CtcfFl/Fl;Prx1Cre hindlimb could also contribute to the
shortened limb phenotype.

To address this possibility, E12.5 hindlimb cryosections were

fluorescently stained for proliferating cell nuclear antigen (PCNA), a marker of cellular
proliferation. Both control and Ctcf-null hindlimbs showed a relatively uniform distribution of
PCNA protein across the entire limb bud, although the intensity of staining did appear to be
variable (Figure 3.8A). Additionally, no differences were seen in protein localization at the
cellular level between mutant hindlimbs and controls, and quantification of PCNA-positive cells
indicated no significant difference between genotypes (Figure 3.8B, C). These results indicate
that the shortened hindlimb phenotype may be caused, in part, by increased apoptosis in the early
limb bud.
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Figure 3.7 Fluorescent TUNEL staining for apoptosis in E12.5 limb bud sections from
CtcfFl/Fl;Prx1Cre mice and control littermates.
A. Fluorescent TUNEL staining of forelimb and hindlimb revealed cells positively stained for
apoptosis in frozen sections from E12.5 knockout mice. B. Quantification of TUNEL-positive
cells in a representative area (white box) showed a significant increase in apoptosis in the Ctcfnull animals when compared to controls, and significantly increased apoptosis in the knockout
forelimb when compared to the knockout hindlimb. All data represented are mean ± SD; a, b, c
= P < 0.05 using a two-way ANOVA, columns with different letters are significantly different
from one another; N=3. Scale bar = 250 μm
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Figure 3.8 Immunofluorescent staining for proliferating cell nuclear antigen (PCNA) in
E12.5 hindlimb bud sections from control and CtcfFl/Fl;Prx1Cre mice.
Representative images demonstrating the immunolocalization of PCNA within the E12.5
hindlimb of Ctcf-null animals and control littermates. A. 10x magnification showed an even
distribution of the protein throughout the hindlimb bud.
differences between control and knockout animals.

B. 20x magnification showed no

C. No differences were seen in the

percentage of PCNA-positive cells in a representative area from Ctcf-null animals and control
littermates. N=3, scale bar = 250 μm
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3.4

CtcfFl/Fl;Prx1Cre hindlimbs showed no differences in SOX9 localization when

compared to littermate controls at E12.5, and no differences in relative Sox9 transcript
levels at E12.5 or E13.5.
Our unpublished data indicate an important role for CTCF in maintaining expression of
the Sox9 gene, therefore examining Sox9 transcript and SOX9 protein levels in CtcfFl/Fl;Prx1Cre
mice was important.

To investigate possible alterations in SOX9 protein localization in

CtcfFl/Fl;Prx1Cre animals, E12.5 hindlimb cryosections were fluorescently stained for SOX9.
Both control and Ctcf-null hindlimb buds showed strong localization of SOX9 protein to the
developing digit rays (Figure 3.9A). Furthermore, no significant differences were observed in
protein localization at the cellular level between mutant hindlimbs and controls, and this
observation was further underscored by quantification of SOX9-positive cells in a representative
area, indicating no significant difference between genotypes (Figure 3.9B, C).
To confirm the immunohistochemical results, qRT-PCR was performed on RNA from
whole Ctcf-null and control hindlimb buds at E12.5 and E13.5. An examination of Sox9 gene
expression confirmed no significant difference in expression levels between mutant and control
limb buds at either E12.5 or E13.5 (Figure 3.10A). Based on these data, I conclude that at this
time point, CTCF does not appear to play a role in regulating Sox9 transcript or SOX9 protein
levels.
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Figure 3.9 Immunofluorescent staining for SOX9 in E12.5 hindlimb bud sections from
CtcfFl/Fl;Prx1Cre animals and control littermates.
Representative images demonstrating the immunolocalization of SOX9 within the E12.5
hindlimb of Ctcf-null animals and control littermates. A. 10x magnification showed protein
localization to the developing digit rays. B. 20x magnification showed no noticeable differences
in a representative area from Ctcf-null animals and control littermates. C. No differences were
seen in the percentage of SOX9-positive cells in a representative area from Ctcf-null animals and
control littermates. N=3, scale bar = 250 μm
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Figure 3.10 Relative gene expression of Sox9, Sox5 and Sox6 in CtcfFl/Fl;Prx1Cre and
control hindlimb buds at E12.5 and E13.5.
Whole hindlimb buds were removed from Ctcf-null and control animals at ages E12.5 and E13.5.
RNA was collected and qRT-PCR was utilized to examine Sox trio gene expression. A. No
significant difference in Sox9 expression was seen between control and mutant hindlimb buds at
either time point. B. Sox5 expression was significantly reduced in mutant hindlimb buds at
E13.5 when compared to control hindlimb buds at E12.5. C. No significant difference in Sox6
expression was seen between control and mutant hindlimb buds at either time point. All data
represented are mean ± SD; * = P < 0.05 using a two-way ANOVA; N=4.
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3.5 Relative gene expression levels of Sox5, Sox6, and Col2a1 were unchanged between
CtcfFl/Fl;Prx1Cre hindlimb buds and controls at E12.5 and E13.5, while Acan transcript
levels increased in control limb buds over time.
To follow up on potential changes in chondrogenic differentiation and ECM genes
expressed downstream of Sox9, transcript levels of Sox5, Sox6, Col2a1, and Acan were evaluated
in control and CtcfFl/Fl;Prx1Cre hindlimb buds at E12.5 and E13.5. Sox5 expression was
unchanged between control and Ctcf-null hindlimb buds at E12.5 and E13.5 (Figure 3.10B).
Sox5 expression also showed a trend towards slightly reduced expression in E13.5 control
hindlimbs compared to E12.5 controls, however this trend was not statistically significant
(Figure 3.10B). Finally, Sox6 expression appeared unchanged between Ctcf-null and control
hindlimb buds at both E12.5 and E13.5 time points (Figure 3.10C). Additionally, no significant
differences were noted in relative Col2a1 expression between knockout and control hindlimb
buds at either E12.5 or E13.5 time points (Figure 3.11A). However, there was a significant
increase in Acan expression in control hindlimb buds from E12.5 to E13.5 (Figure 3.11B). The
mutant hindlimb buds failed to show this same increase in expression across time, instead
maintaining almost identical Acan expression levels at both E12.5 and E13.5 (Figure 3.11B),
suggesting that CTCF may have a role in regulating Acan expression at this time point. Results
also suggested, however, that the loss of CTCF did not affect expression of Sox5, Sox6, and
Col2a1 at this embryonic stage.
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Figure 3.11 Relative transcript levels of Col2a1 and Acan in E12.5 and E13.5 control and
CtcfFl/Fl;Prx1Cre hindlimbs.
Whole hindlimb buds were removed from Ctcf-null and control animals at E12.5 and E13.5.
RNA was collected and qRT-PCR was utilized to examine Col2a1 and Acan chondrocyte marker
gene expression. A. No significant difference in Col2a1 expression was seen between control
and mutant hindlimb buds at either time point, although there appeared to be a trend showing
reduced Col2a1 expression in mutant hindlimb buds at E13.5. B. Acan expression was increased
significantly from E12.5 to E13.5 in control hindlimb buds, however there was no significant
increase in Acan expression in the mutant hindlimb buds at E13.5 when compared with E12.5
control hindlimbs. All data represented are mean ± SD; * = P < 0.05 using a two-way ANOVA;
N=4.
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3.6 Long non-coding RNAs at the Sox9 gene locus, BC006965 and D17Rik, showed relative
expression changes between genotypes or developmental stages in the hindlimb bud, while
expression levels of Kcnj2 and Slc39a11, genes bordering the Sox9 locus, did not change.
To follow up on potential expression changes in the two long non-coding RNAs present
at the Sox9 locus, BC006965 and D17Rik transcript levels were examined in CtcfFl/Fl;Prx1Cre
and control hindlimbs at E12.5 and E13.5. BC006965 showed no difference in expression
between Ctcf-null hindlimb buds and control at each time point examined; however, both control
and mutant hindlimb buds showed significantly increased gene expression at E13.5 when
compared to E12.5 (Figure 3.12A). Furthermore, D17Rik expression showed no significant
changes between genotypes at either E12.5 or E13.5 (Figure 3.12B). Furthermore, I examined
potential expression changes in genes bordering the Sox9 locus, Kcnj2 and Slc39a11. While
there were no significant differences in relative Kcnj2 expression between Ctcf-null and control
hindlimbs at both time points, there was a trend towards a slight reduction in gene expression in
mutant hindlimbs at E13.5 (Figure 3.13A). No significant changes were observed in Slc39a11
expression levels between either genotypes or developmental stages (Figure 3.13B). Taken
together, these results suggest that CTCF does not appear to play a critical role in regulating
either lncRNAs at the Sox9 gene locus, or neighbouring genes.
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Figure 3.12 Relative gene expression of long non-coding RNAs BC006965 and D17Rik in
CtcfFl/Fl;Prx1Cre and control hindlimb buds at ages E12.5 and E13.5.
Whole hindlimb buds were removed from Ctcf-null and control animals at E12.5 and E13.5.
RNA was collected and qRT-PCR was utilized to examine gene expression of the long noncoding RNAs BC006965 and D17Rik. A. While BC006965 expression did not differ between
genotype at either time point, both control and knockout hindlimb buds showed significantly
increased expression at E13.5 when compared to E12.5. B. D17Rik expression was significantly
higher in the mutant hindlimb bud at E12.5 when compared to control hindlimb buds at E13.5.
All data represented are mean ± SD; *, a, b = P < 0.05 using a two-way ANOVA, columns with
different letter labels are significantly different; N=4.
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Figure 3.13 Relative transcript levels of the genes bordering the Sox9 gene locus, Kcnj2
and Slc39a11, in E12.5 and E13.5 CtcfFl/Fl;Prx1Cre and control hindlimb buds.
Whole hindlimb buds were removed from Ctcf-null and control animals at E12.5 and E13.5.
RNA was collected and qRT-PCR was utilized to examine Kcnj2 and Slc39a11 gene expression.
A. No significant difference in Kcnj2 expression was seen between control and mutant hindlimb
buds at either time point, although there appeared to be a trend showing reduced Kcnj2
expression in mutant hindlimb buds at E13.5.

B. No significant difference in Slc39a11

expression was seen between control and mutant hindlimb buds at either time point. All data
represented are mean ± SD; * = P < 0.05 using a two-way ANOVA; N=3.
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3.7 No gene expression changes were seen in Cdh-2 or Cdh-11 in hindlimb buds of Ctcf-null
or control animals at E12.5 or E13.5.
Proper cell-cell adhesion is critical to mesenchymal condensations and chondrogenesis
and involves the expression of cell-cell adhesion molecules Cadherin-2 and Cadherin-11. To
investigate potential aberrations in cell-cell adhesion within the CtcfFl/Fl;Prx1Cre hindlimb,
transcript levels of Cdh-2 and Cdh-11 were evaluated E12.5 and E13.5 in mutant and control
hindlimb buds. No discernible trends or significant differences were discovered in relative
expression levels for both genes when examining Ctcf-null and control hindlimb buds at either
time point (Figure 3.14A, B). Therefore, these findings suggest that CTCF does not appear to
play a significant role in regulating cadherin-mediated cell-cell adhesion in the developing
hindlimb at this time point.
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Figure 3.14 Relative gene expression of Cdh-2 and Cdh-11 in control and CtcfFl/Fl;Prx1Cre
hindlimb buds at E12.5 and E13.5.
Whole hindlimb buds were removed from Ctcf-null and control animals at E12.5 and E13.5.
RNA was collected and qRT-PCR was utilized to examine Cdh-2 and Cdh-11 gene expression.
A. No significant difference in Cdh-2 expression was seen between control and mutant hindlimb
buds at either time point. B. No significant difference was seen in Cdh-11 expression between
control and mutant hindlimb buds at either time point. All data represented are mean ± SD; * =
P < 0.05 using a two-way ANOVA; N=4.
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3.8

Tibiae from E15.5 CtcfFl/Fl;Prx1Cre mice displayed severe growth plate and

mineralization defects.
To gain a better understanding of growth plate structure and development in the
CtcfFl/Fl;Prx1Cre long bones, mutant and control tibiae were collected at E15.5 then sectioned
and stained with Safranin-O/Fast Green, Von Kossa, or p57 antibody that detected cartilaginous
proteoglycans, cartilage mineralization, and terminally differentiated cells, respectively.
Safranin-O/Fast Green staining confirmed that mutant tibiae were severely shortened at E15.5,
and had few hypertrophic chondrocytes (Figure 3.15). When stained by Von Kossa, Ctcf-null
tibiae also showed no mineralized cartilage when compared to control littermates (Figure
3.16A).

Finally, immunostaining was performed for p57, a marker of cell cycle exit and

prehypertrophic chondrocyte differentiation. Mutant tibiae showed a shortened region of cells
positively-stained for p57 (Figure 3.16B). The resting and proliferating zones of the growth
plate, which did not show p57 staining, were then measured and showed significantly shorter
zone length than control littermates (Figure 3.16C). Notably, the tissue surrounding the tibia
also stained positively for p57.

These results indicate that Ctcf-null mice have delayed

chondrocyte differentiation, as well as shorter proliferative and hypertrophic zones, which likely
contributes to the shortened hindlimb length.
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Figure 3.15 Safranin-O/Fast Green staining of CtcfFl/Fl;Prx1Cre and control tibiae at E15.5.
Sections from E15.5 tibiae were stained with Safranin-O/Fast Green and morphology was
examined. Representative images demonstrate tibiae from Ctcf-null animals (outlined in yellow
rectangle) were shorter than control littermates and possess shorter resting, proliferative, and
hypertrophic zones. Scale bar = 100 μm
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Figure 3.16 Von Kossa staining and immunostaining for p57 in CtcfFl/Fl;Prx1Cre and
control littermate tibiae at E15.5.
Sections of E15.5 Ctcf-null and control tibiae were stained with Von Kossa for mineralized
cartilage, and terminal differentiation marker p57. A. Von Kossa staining demonstrated that
mutant tibiae lack all mineralization (brown staining) at E15.5. B. Immunostaining for p57 in
the prehypertrophic and hypertrophic chondrocytes showed reduced staining in mutant tibiae
when compared to control littermates. Resting and proliferating zones are indicated by a yellow
bar. C. Quantification of the resting and proliferating zones demonstrated a significant decrease
in zone length in mutant tibiae, when compared with controls. Data represented are mean ± SD;
* = P < 0.05 using an unpaired T-test; N=3. Scale bar = 100 μm
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3.9 CtcfFl/Fl;Prx1Cre skeletons showed severely malformed hindlimbs with oligodactyly and
reduced mineralization in the long bones, and calvarial defects at P0.
To examine the skeletal defects in more detail, whole skeletons from CtcfFl/Fl;Prx1Cre
and control animals were collected at P0 and stained with Alcian blue/Alizarin red for cartilage
and mineralized bone, respectively. The Ctcf-null skeletons confirmed the truncated forelimbs
and severely shortened hindlimbs with oligodactyly (Figure 3.17A, B). The total length of each
of the long bones was measured and results indicated that the femur, tibia, and fibula are
significantly shorter in Ctcf-null animals than in control littermates (Figure 3.17C).
Measurements of the mineralized zone as a percentage of total bone length also indicated that the
mutant tibia and fibula have significantly less mineralization than controls, even after
normalization to total length (Figure 3.17D). An examination of the skull also showed severe
calvarial defects. Ctcf-null mice were missing portions of the interparietal (IP), parietal (P),
frontal (F), and nasal (N) skull plates, which are labeled with corresponding letters on the control
skull (Figure 3.18A). Both the palate and jaw of the mutant animals, however, appeared
morphologically normal when compared to controls (Figure 3.18B, C). Therefore, these results
suggest a role for CTCF in both endochondral and intramembranous ossification, and
CtcfFl/Fl;Prx1Cre mice appear to have delayed chondrocyte differentiation and cartilage
mineralization.
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Figure 3.17 Skeletal preparations of CtcfFl/Fl;Prx1Cre animals and littermate controls at
P0, double stained with Alcian blue and Alizarin red.
Skeletons from Ctcf-null animals and control littermates were stained with Alcian blue and
Alizarin red, then examined and measured for morphological differences in long bone length and
mineralized zone. A. Whole skeletons of the Ctcf-null animals had severely truncated forelimbs
and shortened hindlimbs. B. Hindlimbs of mutant animals were shorter than control littermates
and also presented with oligodactyly. C. Mutant femurs, tibiae, and fibulae were significantly
shorter than in littermate controls. D. The tibia and fibula in mutant hindlimbs had significantly
shorter mineralized zones, as a proportion of total bone length, when compared to littermate
controls. All data represented are mean ± SD, * = P < 0.05 using an unpaired T-test; N=3. Scale
bar = 5 mm for whole body and 3 mm for hindlimbs
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Figure 3.18 Comparison of the skull vault, palate, and jaw between CtcfFl/Fl;Prx1Cre mice
and control littermates at P0.
Skeletons from Ctcf-null animals and control littermates were stained with Alcian blue and
Alizarin red, then examined for morphological differences.

A. Ctcf-null animals displayed

severe skull defects and an open skull vault missing portions of the interparietal (IP), parietal (P),
frontal (F) and nasal (N) skull plates, labeled with the corresponding letter on the control skull,
and outlined in yellow in the mutant skull. B. No differences were noted in the palates of mutant
animals and controls. C. No differences were noted in jaw size or morphology of mutant
animals and controls. N=3, scale bar = 3 mm
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4.0 DISCUSSION
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4.1

Summary of Results
The relationship between epigenetic regulation and developmental biology is becoming

increasingly complex and exciting. However, the role of chromatin organizers, such as CTCF, in
the development of the hindlimb and skeleton is currently unknown.

Previous studies by

Soshnikova et al. demonstrated the importance of CTCF in cell survival in the developing
forelimb of CtcfFl/Fl;Prx1Cre mice83.

Moreover, unpublished studies from our lab using

CtcfFl/Fl;Col2Cre mice (which lack CTCF in developing cartilage) indicate an important role for
CTCF in maintaining Sox9 expression in cartilage (Bush et al., in prep.). These mice present
with a slight, but significant reduction in both Sox9 gene and SOX9 protein expression, altered
growth plates with fewer and smaller hypertrophic chondrocytes, and campomelia - a phenotype
that resembles the human disease Campomelic Dysplasia. The CtcfFl/Fl;Col2Cre mouse model,
however, involves Ctcf deletion after the onset of Sox9 expression. Therefore, both these CTCFdeficient animal models, as well as de novo CTCF mutations in humans, suggest a role for CTCF
in regulating limb and cartilage development. I used the published model of CTCF deficiency in
the developing limb, as presented by Soshnikova et al., to examine the effects of Ctcf deletion in
the developing hindlimb83. My objective was to investigate the effects of CTCF deletion on
chondrogenesis and skeletal development in the hindlimb of CtcfFl/Fl;Prx1Cre mice, which
presents an intermediate phenotype between the severely malformed CtcfFl/Fl;Prx1Cre forelimb
and the mildly disfigured CtcfFl/Fl;Col2Cre hindlimb.
Micromass cultures from wild-type forelimbs and hindlimbs were utilized to explore the
possibility of differential chondrogenic gene expression between limbs as a contributor to
phenotypic activity. Gene expression analysis was performed by qRT-PCR on key chondrogenic
genes, and the long non-coding RNA encoded at the Sox9 locus, BC006965. Results revealed a
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statistically significant 3.5-fold increase in Sox9 expression in the developing forelimb 48 hours
after plating, and 4-fold increase at 60 hours post-plating, while expression in the hindlimb
appeared to increase over time, but these results were not statistically significant.

Sox5

expression differed between the limbs, showing an increase in expression in the forelimb
immediately after plating, then maintenance of expression levels from 24 to 36h before the
transcript levels returned to baseline at 60 hours post-plating. The hindlimb, however, showed a
steady increase in Sox5 transcript levels over the time course, and reached a higher transcript
level after 60 hours than the forelimb. Sox6 expression also showed a trend towards increasing
expression in both the forelimb and hindlimb over the time course. Additionally, both Col2a1
and Acan show steadily increasing expression in both forelimb and hindlimb cultures across all
time points. Col2a1 expression is significantly higher at 60 hours post-plating in both forelimbs
and hindlimbs, while Acan expression is significantly higher only in the forelimb at 60 hours.
Finally, I investigated expression levels of the long non-coding RNA BC006965 to examine a
potential relationship with the regulation of Sox9. Transcript levels also show trends towards
increasing expression over time in both forelimb and hindlimb micromass cultures.
Interestingly, when expression patterns of Sox9 and BC006965 are compared in hindlimb
micromass cultures, they reveal almost identical changes in transcript levels at each time point.
Taken together, these results suggests that chondrogenesis appears to occur more rapidly in
developing forelimbs, and expression of the Sox9 and BC006965 genes may be regulated in the
same manner. These phenotypic differences between forelimbs and hindlimbs, provide a further
rationale for examining the development of the hindlimb in CtcfFl/Fl;Prx1Cre mice.
Loss of CTCF in CtcfFl/Fl;Prx1Cre mice was validated through immunostaining and qRTPCR. Ctcf-null hindlimbs at age E12.5 revealed a 70% decrease in Ctcf mRNA, and a reduction
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of CTCF protein in the limb bud mesoderm. An examination of gross morphology revealed the
severe limb malformations previously published, as well as a novel skull phenotype, discussed
below. Apoptosis in the developing hindlimb was then examined using a fluorescent TUNEL kit
on E12.5 limb cryosections, which demonstrated that the mutant hindlimb has significantly more
apoptosis than littermate controls, but significantly less apoptosis than corresponding mutant
forelimbs. The levels of cell death in the forelimb and hindlimb appear to correlate with the
severity of the overall limb phenotype, suggesting that it may contribute to the phenotypic
differences seen between limbs.

Another possible cause of limb shortening is a defect in

proliferation, which I examined in the E12.5 hindlimb.

Staining for PCNA revealed no

significant differences in proliferation at that time point; thus it does not appear that defects in
cell proliferation are contributing to the phenotype at this embryonic stage.
Given our unpublished data (Bush et al., in prep) indicating a role for CTCF in
maintaining Sox9 gene expression, investigating Sox9 transcript and SOX9 protein levels in
CtcfFl/Fl;Prx1Cre hindlimbs was important. Immunofluorescent staining for SOX9 protein at
E12.5 revealed no significant differences in SOX9 protein distribution between control and
mutant animals at that time. Sox9 transcripts also showed no differences between genotypes at
E12.5 and E13.5.
To investigate potential changes in chondrogenic marker genes, ECM genes, and genes
related to the Sox9 locus, transcript levels of Sox5, Sox6, Col2a1, Acan, BC006965, D17Rik,
Kcnj2, and Slc39a11 were analyzed in control and Ctcf-null animals at ages E12.5 and E13.5.
No changes in Sox5 or Sox6 transcript levels were seen between genotypes at either time point.
Col2a1 expression is also not different between genotypes or time, although mutant hindlimbs at
E13.5 do appear to show a trend toward lower expression. In contrast, Acan expression is
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significantly higher in the E13.5 control limb bud, compared to E12.5 controls, but there is no
corresponding increase in expression in the mutant hindlimb at E13.5. Both BC006965 and
D17Rik demonstrate no significant difference across time or genotype in expression, although
there is a marked trend towards increased BC006965 expression in both control and mutant
hindlimbs at E13.5. The two genes bordering the Sox9 locus, Kcnj2 and Slc39a11, were also
examined, but showed no significant changes, suggesting they are regulated independently of
Sox9. Finally, gene expression changes for Cdh-2 and Cdh-11 were also examined to rule out
potential defects in cell-cell adhesion in early mesenchymal condensations, but no significant
differences were seen. Taken together, these results suggest that CTCF may have a role in
regulating Acan expression in early limb development, however it does not contribute to
regulation of other cartilage and ECM markers, as well as Sox9 locus-related genes and cell-cell
adhesion markers examined.
To gain a better understanding of the role of CTCF in growth plate structure and
development, CtcfFl/Fl;Prx1Cre long bones were examined via histology at E15.5.

Tibial

sections were stained with Safranin-O/Fast Green, and Von Kossa, and immunohistochemistry
was performed for cell cycle exit marker p57. Safranin-O staining revealed disorganized growth
plates with fewer hypertrophic chondrocytes in the mutant tibia. Mutant tibiae also failed to
mineralize at E15.5, although control counterparts demonstrated significant mineralization. p57
staining and measurements of the resting and proliferating zones also revealed that each growth
plate zone is significantly shorter in Ctcf-null animals. Therefore, CtcfFl/Fl;Prx1Cre mice appear
to have a delay in chondrocyte differentiation and severe growth plate defects.
Finally, the skeletons were examined at P0 using Alcian blue/Alizarin red double staining
for cartilage and mineralized bone. After birth, Ctcf-null mice show severe hindlimb defects and
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oligodactyly, and the femur, tibia, and fibula are all significantly shorter than control
counterparts. Interestingly, P0 tibiae show mineralization, however the amount of mineralization
as a proportion of total bone length is significantly reduced in the tibia and fibula of Ctcf-null
mice. Furthermore, mutant mice are missing portions of each of the interparietal, parietal,
frontal, and nasal skull plates.

These findings suggest that CTCF is critical for proper

chondrogenesis and hindlimb development, as well as skull development.

4.2

Contribution to the Current State of Knowledge of CTCF in Hindlimb Development

and Potential Future Studies
The role of CTCF in limb development was first described by Soshnikova et al. in 2010
through analysis of the developing forelimb in CtcfFl/Fl;Prx1Cre mice. Ctcf-null forelimbs were
described as undergoing massive amounts of apoptosis, which was correlated to up-regulation of
the pro-apoptotic gene Puma (p53 up-regulated modulator of apoptosis), contributing to the
severe defect and total abrogation of limb growth. Additionally, although genome-wide studies
identified CTCF binding sites within and surrounding the HOXD cluster, Soshnikova et al. found
that the Hoxd genes were not regulated by CTCF. These studies, however, did not investigate
the effects of CTCF inactivation in the developing hindlimb, which presented with a less severe
phenotype. Moreover, unpublished data from our lab suggest a role of CTCF in maintaining
Sox9 expression, however the effects of deletion of Ctcf prior to the onset of chondrogenesis
have not yet been investigated. Therefore, the studies presented in this thesis are the first to
examine the hindlimb of CtcfFl/Fl;Prx1Cre mice in detail at the molecular level.
I confirmed that, as presented by Soshnikova et al., loss of CTCF in the developing
forelimb leads to an increase in apoptosis, which we also observe in the mutant hindlimb 83.
However, the reduced amount of apoptosis in the Ctcf-null hindlimb (compared to the mutant
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forelimb) might account for its less severe phenotype. I speculate that the reduced level of
apoptosis seen in the hindlimb is correlated with reduced Cre expression in the hindlimb
compared to the forelimb83,90,91. The population of cells that escape Cre inactivation and are not
Ctcf-null in the hindlimb is therefore greater that in the corresponding forelimb, which likely
contributes to the less severe phenotype. I speculate that the increased cell death in the hindlimb
may also be correlated to up-regulation of the p53 effector PUMA, as seen in the mutant
forelimb. CTCF is a known repressor of PUMA, and has been shown to bind with cohesin
intragenically at the PUMA locus to dampen expression of PUMA92. Moreover, PUMA was also
up-regulated in the Ctcf-null developing forebrain studied by Watson et al., and deletion of both
Ctcf and Puma in the embryonic brain rescued Ctcf-null neuroprogenitor apoptosis84. Taken
together these results suggest that loss of CTCF in the hindlimb may lead to PUMA upregulation, thereby causing apoptosis. Further investigations into Puma expression and function
in the Ctcf-null hindlimb would be needed to confirm this hypothesis.
My investigation into proliferation also confirmed results reported by Soshnikova et al.
where Ctcf mutant forelimbs showed normal cell proliferation at E11.583. The PCNA-stained
hindlimbs at age E12.5 showed no differences in proliferation between control and Ctcf-null
hindlimbs, as we expected. This finding also provides insight into the phenotypic differences
between the developing forelimb and hindlimb in CtcfFl/Fl;Prx1Cre mice, suggesting that cell
proliferation does not contribute to the differences witnessed, and that CTCF is not critical for
regulating proliferation at this stage of development. It is important to note, however, that
immunostaining analysis of proliferation is not as sensitive as detection of DNA synthesis with
BrdU or EdU, and future experiments confirming proliferation using a thymidine analogue
method would be appropriate.
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During the mesenchymal condensation stage at E12.5 immediately preceding
chondrogenic differentiation, CTCF does not appear to be important in regulating the onset of
Sox9 transcript expression or SOX9 protein localization. These data are in agreement with the
absence of changes in levels of Sox5 and Sox6 transcripts between control and Ctcf-null mice at
these time points. This finding was somewhat unexpected given our lab's data on CTCF binding
to the Sox9 locus and its critical role in maintaining Sox9 expression in cartilage (Bush et al., in
prep.). Thus, the absence of changes in the expression of most other examined genes was not
surprising, since most of them are regulated by SOX9. Our data suggest that CTCF plays
different roles in the regulation of Sox9 expression at different developmental stages; the
molecular basis of this interesting phenomenon is unknown, but should be examined in the
future. For such studies, it will be essential to determine how CTCF regulates DNA looping and
epigenetic events (DNA methylation, histone modifications etc.) in the Sox9 locus.
CTCF loss did not affect the expression of the critical cartilage ECM gene Col2a1 at
either E12.5 or E13.5 in the hindlimb bud, however Acan expression failed to increase in the
mutant hindlimb at E13.5. Since Sox9 does not appear affected in the mutants at this stage, these
data suggest that CTCF regulates Acan expression through other mechanisms. Deletion of Ctcf
leads to a disrupted growth plate with shorter resting and proliferative zones, as well as fewer
hypertrophic chondrocytes.

Interestingly, the shortened hypertrophic zone seen in

CtcfFl/Fl;Prx1Cre mice is similar to the growth plates in humans with CCD, caused by
haploinsufficiency of RUNX246. Additionally, mutant tibiae fail to mineralize at E15.5, but have
some mineralization by birth, although significantly less than controls.

The mineralization

defects suggest that CTCF may, in part, regulate cartilage mineralization in the long bones.
Taken together, these results provide strong evidence for CTCF as a regulator of chondrocyte
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differentiation and progression through the chondrocyte life cycle, perhaps through regulation of
Runx2. These results also suggest a potential explanation for the short stature seen in human
patients with heterozygous mutations in CTCF.
In contrast to long bone development, the skull is formed through intramembranous
ossification. The murine skull is composed largely of parietal and frontal skull plates, which are
derived from cephalic mesoderm and cranial neural crest cells, respectively. Here I show that
CTCF is important for normal development of the cranial vault. The CtcfFl/Fl;Prx1Cre mice are
born with large holes in their skull, and lack portions of each of the parietal, frontal, nasal, and
interparietal calvariae, or skull plates. No previous studies have implicated CTCF in skull
development or intramembranous ossification, thus the novelty of this result should be
underscored. Interestingly, the poorly developed skull is remarkably similar to, but slightly less
severe than that described for conditional knockout mice for transforming growth factor beta
(TGF) reported by Seo and Serra in 2009. The Tgfb2Fl/Fl;Prx1Cre mice are also neonatal lethal
and are born with an open skull.

Their studies demonstrate that while slightly reduced

proliferation in the developing skull vault may contribute to the phenotype, there is a significant
down-regulation of both Runx2 and Osterix (OSX) expression in the mutant embryos, suggesting
altered osteoblast differentiation. Given the similarity of the phenotypes, one possibility is that
CTCF may play a role in regulating RUNX2, OSX, or both, potentially through TGF, and future
studies should consider investigating these factors.
It is also possible that CTCF function in tissues surrounding the developing skeleton
contributes to the phenotype seen in the CtcfFl/Fl;Prx1Cre mice. Both paracrine or biomechanical
mechanisms should be considered, and tendons are a potential candidate tissue to investigate
further. The Prx1 enhancer used to drive Cre expression in CtcfFl/Fl;Prx1Cre mice is expressed
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in the tendons of the forelimb and hindlimb buds by E15.590. CTCF function has not yet been
investigated in tenogenic cells, yet it seems critical for all tissues in which it has been examined,
therefore we speculate that the deficiency of CTCF in tendons could lead to chemical or physical
force alterations, or both. Generation and analysis of a mouse with the conditional deletion of
CTCF in tendons using a Scleraxis Cre driver would be a reasonable way to approach these
postulations.
Finally, my studies suggest subtle differences in chondrogenesis between forelimbs and
hindlimbs. It is well established that development proceeds from cranial to caudal; thus, a slight
delay in development of the hindlimb is expected. However, my data also suggest some
variances in the patterns of chondrogenic gene induction between the limbs. On the other hand,
some of the experimental limitations discussed below resulted in large variability between trials,
especially for the hindlimb; thus, further investigations are required to characterize the
differences between forelimb and hindlimb.

4.3

Limitations of Research and Alternative Approaches
In the studies presented, an in vitro micromass culture system was utilized. This culture

method allows investigators to examine chondrogenic tissue formation in a controlled
environment without artificial materials and is well-established in the field of skeletal
biology88,89,93. However, mesenchymal cells are pluripotent and can differentiate into other noncartilaginous tissues, such as adipose tissue, muscle, and bone. Although previous studies in our
lab demonstrated an increase in cartilage-specific markers and gene expression over time, in
conjunction with a decrease in gene expression for markers of other cell types, the differentiation
of these cells into chondrocytes is density-dependent. Cells on the periphery of these micromass
cultures are subject to slightly different conditions, and therefore the potential exists for
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additional cell types to be present within these cultures. This results in increased variability in
gene expression analyses, which we did observe, especially in the hindlimb micromass cultures.
Another cause of this variability is the exact time between fertilization and harvest of embryos
that can vary from litter to litter (as discussed further below). This will particularly affect the
hindlimb as it is developmentally delayed compared to the forelimb.
The CtcfFl/Fl;Prx1Cre mouse model used in these studies was originally published in
2010 by Soshnikova et al83. This mouse model involves the conditional loss of CTCF in early
limb mesenchyme, prior to the onset of chondrogenesis. The Prx1 Cre driver is well-established
in the limb development field for examining limb-specific effects of a certain gene, however
there are certain limitations to this mouse model use of this model90,91. First, Prx1 is not as
robustly expressed in the developing hindlimb as in the forelimb, and Cre expression is therefore
considered “leaky”. Because a number of cells escape Cre inactivation, there is still CTCF
protein present in the mutant mouse hindlimb. The presence of any amount of CTCF is a
confounding factor when considering results, particularly differences between the forelimb and
hindlimb phenotype in these mice. Second, a mesenchyme-specific Cre driver leads to deletion
of Ctcf in chondrogenic precursor cells, as well as progenitors for other cell types such as
tendons and osteoblasts90,91,94,95. This consideration is important because of the large number of
interactions between tissue types during development. Furthermore, the deletion of Ctcf in
developing tissue and tissue surrounding the cartilage elements may contribute to the limb
defects witnessed and the severity of the phenotype in CtcfFl/Fl;Prx1 mice compared to
CtcfFl/Fl;Col2 mice with Ctcf-null cartilage. The loss of CTCF in multiple tissues therefore
makes it difficult to pinpoint a specific role for the protein in one individual tissue. This model
is, however, beneficial when examining a more global role for CTCF in a developing body part.
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Third, Prx1 expression is not just limited to the developing limb mesenchyme. Ctcf is therefore
conditionally deleted in other tissues including the skull mesenchyme, forebrain, and developing
heart valves. The loss of CTCF in multiple tissues leads to difficulty in discerning the cause for
the neonatal lethality of the mutant mice.
Beyond limitations of the mouse model utilized, there are technical limitations to these
studies as well. Mice were mated in a timed process, as described in methods, and all dissections
took place at 10 am to reduce variability. However, timed matings do not guarantee that all
embryos are the same age at the time of dissection. Both the time of mating and fertilization
contributes to variability between embryonic age; therefore, although the hindlimb tissue taken
from mutant and control mice for RNA isolation and gene expression analyses were assumed to
be E12.5, there is some variability between litters. These studies would thus benefit from
increasing the number of trials to ensure the studies have enough power. Additionally, the whole
hindlimb bud was taken from mutant and control embryos, including the ectoderm, in which Ctcf
was not deleted. Inclusion of the CTCF-rich ectoderm in the samples taken for qRT-PCR
analyses may have confounded the results, and future studies should involve microdissection of
just mesenchymal tissue.

Another significant limitation to these studies involved mouse

breeding issues. Although the colonies were closely monitored and taken care of in accordance
with all animal breeding protocols at Western University, I encountered difficulty when breeding
mice for experiments and was limited by the small number of litters containing both mutant and
control animals. This lack of animals for use in experiments led to the decision of examining
only E12.5, E15.5, and P0 animals. Although these three time points have led to a wealth of
information on the role of CTCF in the developing hindlimb, examining additional time points is
advisable to produce a more complete time course. Future studies should examine histology and
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immunofluorescence at E13.5, and histology at E14.5, E16.5, and E17.5 to pinpoint the earliest
onset of the phenotype, and when mineralization occurs in mutant tibiae.
Finally, my findings raised multiple interesting questions that should be followed up with
additional experiments. First, previous studies in our lab have examined CTCF binding to
genomic DNA in developing wild-type cartilage at E15.5. Performing RNA sequencing (RNAseq) on cartilage from CtcfFl/Fl;Prx1Cre tibiae at E15.5 to detect key target genes would be an
appropriate follow-up. Genes identified by RNA-seq as having altered transcription in Ctcf-null
hindlimbs could then be compared to CTCF-binding in normal cartilage, and a list of target
genes could be compiled. This experiment would help narrow the focus to the specific role of
CTCF in developing cartilage. Once target genes have been identified, performing circularized
chromosome conformation capture (4C) and chromosome conformation capture (3C) may be of
interest to detect chromosomal interactions at target gene loci and provide more insight into the
mechanism of CTCF-mediated gene regulation. Moreover, performing ChIP-seq for cohesin
binding and other epigenetic markers (e.g. histone modifications) in the wild type and Ctcf-null
hindlimb would provide mechanistic insights into how CTCF controls DNA looping and gene
expression.
Additionally, my studies have shown growth plate abnormalities in Ctcf-null tibia, and a
failure or delay of chondrocytes to become hypertrophic. Use of a CtcfFl/Fl;Col10Cre mouse line
to conditionally delete CTCF in hypertrophic chondrocytes would undoubtedly provide more
insight into this interesting phenotype and the role of CTCF in chondrocyte differentiation.
Furthermore, evidence indicates the importance of CTCF in proper cartilage and long bone
development, however both the CtcfFl/Fl;Prx1Cre and CtcfFl/Fl;Col2Cre mice are neonatal lethal.
Using the tamoxifen-inducible CtcfFl/Fl;Aggrecan-CreER(T2) mouse model would allow the
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depletion of CTCF in developing or adult cartilage at various time points. In particular, this
mouse model would allow an investigation into the role of CTCF in adult cartilage and a
potential role for CTCF in age-related cartilage diseases such as osteoarthritis. Finally, these
studies have provided evidence for a role of CTCF in the developing skull. This result is novel
and given the severity of the calvarial defects, an investigation into the role of CTCF in
intramembranous ossification and specifically skull development is advised.

These studies

should include histology to examine proliferation and apoptosis in the developing skull vault, as
well as investigation of osteoblast differentiation markers.

4.4

Significance
Human limb malformations are a type of congenital anomaly with a major burden on

individuals, families and the public health system. The 2013 Congenital Anomalies in Canada
Report by the Public Health Agency stated that Limb Deficiency Defects are characterized by
total or partial absence of a limb, or a smaller portion, and occur in three to eight infants per
10,000 live births. Limb defects, however, are a heterogeneous group of malformations and limb
development is a highly complex process that is not yet completely understood. Knowledge of
the regulation of chondrogenesis and skeletal development in the hindlimb is critical for
understanding both normal and pathological limb development. Particularly, elucidating the role
of chromatin organizers such as CTCF will shed light on the regulation of key genes involved in
chondrogenesis and help provide a more global understanding of severe chondrodysplasias. The
studies in this thesis have underscored the importance of CTCF in proper hindlimb development
and endochondral ossification, and provided insight into the phenotype seen in human patients
with mutations in CTCF. My work suggests that CTCF is an important regulator of the cartilage
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growth plate and proper mineralization of developing long bones, and is critical for preventing
apoptosis in the developing limb. In conclusion, these studies have contributed valuable insights
into chondrogenesis and hindlimb development, and may ultimately lead to improved detection
and treatments of limb and skeletal malformations.
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APPENDIX
Animal Use Protocol

2007-045-06::7:

AUP Number: 2007-045-06
AUP Title: Regulation of Endochondral Bone Growth by Hormones

Yearly Renewal Date: 08/01/2014

The YEARLY RENEWAL to Animal Use Protocol (AUP) 2007-045-06 has been approved, and will be approved
for one year following the above review date.

1.

This AUP number must be indicated when ordering animals for this project.

2.

Animals for other projects may not be ordered under this AUP number.

3.

Purchases of animals other than through this system must be cleared through the ACVS office.
Health certificates will be required.

REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar with
the contents of this document.

The holder of this Animal Use Protocol is responsible to ensure that all associated safety components (biosafety,
radiation safety, general laboratory safety) comply with institutional safety standards and have received all necessary
approvals. Please consult directly with your institutional safety officers.

Submitted by: Kinchlea, Will D
on behalf of the Animal Use Subcommittee
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